pancreatic cancer Europe's Drug Advisers Back a Pancreatic Cancer Pill That Added Months EU drug advisers backed daraxonrasib for metastatic pancreatic cancer after a phase 3 trial reported median survival of 13.2 months versus 6.7 on chemotherapy. The Commission has not yet authorised it.
Health & Medicine Breakthrough Pancreatic Cancer Drug Doubles Survival Time New drug daraxonrasib achieves unprecedented survival benefits in pancreatic cancer by targeting the previously "undruggable" KRAS mutation.
Health & Medicine The Drug Combo That's Giving Pancreatic Cancer Patients New Hope Atebimetinib combination therapy achieves compelling one-year survival rates in pancreatic cancer patients, offering new hope for historically treatment-resistant disease.
